Altria (MO)
NYSEConsumer StaplesTobaccoSnapshot 2026-10-30
$78.03+1.67%
Close 2026-10-30 · 1-day change
NYSEConsumer StaplesTobaccoSnapshot 2026-10-30
Research Workspace
Put MO beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Consumer Staples is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 0% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 17%.
View QualityManagement screens strong on capital allocation, earnings delivery, the balance sheet, market reaction to earnings.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationRelatively steady — typically moves about 1% a day.
View RiskMO’s case rests on shareholder returns, supported by adjusted earnings growth despite modest revenue growth. Q3 revenue grew 1.0% year over year, and adjusted EPS beat estimates by 0.7%. The P/E is 14× versus a 16× peer median, despite its own historical 12× multiple. The market is pricing in more growth than our forecast. Domestic cigarette volume fell 3%, and the next-quarter miss probability is 23%. The valuation read says peer multiples imply a price roughly in line with where it trades (about fair). Our read remains intact; this read is provisional.
Trailing returns as of 2026-10-30. MO is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 14 analysts currently covering MO (as of Oct 2026).
Based on 5 Wall Street analysts offering 12-month price targets for MO in the last 4 months.
Continue this research
Compare MO with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| MO Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Tobacco — fair value, gap to price, and forward P/E.
Compare the value case
Put MO next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Deliver adjusted diluted EPS growth
2026 EPS guidance supports growth; an additional $1B buyback advances shareholder returns.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $78.03
The last 12 months of price, then the range of analyst 12-month targets from today’s $78.03.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Deliver adjusted diluted EPS growth
Raised guidance after beating estimates, supporting adjusted EPS growth expectations.
Threatens: Deliver EPS growth
Negative equity and margins threaten EPS growth.
Concerns about dividend sustainability challenge capital allocation strategy.
Highlights Altria's competitive position in smoke-free products.
Threatens: Return significant value to shareholders via dividends and share repurchases
Lawsuit against FDA may impact dividend sustainability.
Advances: Return significant value to shareholders via dividends and share repurchases
Significant shareholder returns align with capital allocation objectives.
Threatens: Advance smoke-free product portfolio expansion
Rising dividends amid declining cigarette sales is concerning.
